Market Overview

Supernus Pharmaceuticals Reports Positive Phase IIb Results on SPN-810 for Treatment of Impulsive Aggression in ADHD Patients

Share:

Supernus Pharmaceuticals (NASDAQ: SUPN) received positive topline results from its Phase IIb study on SPN-810 for the treatment of impulsive aggression in ADHD patients.

The study is a multicenter randomized, double-blind, placebo controlled clinical trial in children 6 to 12 diagnosed with Attention Deficit and Hyperactivity Disorder (ADHD) and characterized by impulsive aggression that is not controlled by optimal stimulant and psychosocial treatment. A total of 121 patients were randomized in the study across placebo and three doses of SPN-810.

The primary endpoints in the study were the effect in reducing impulsive aggression as measured with change in the score of the Retrospective - Modified Overt Aggression Scale "R-MOAS", and the rate of remission of aggression, after at least three weeks of treatment. Secondary endpoints included safety and tolerability of SPN-810 as well as the effect on the Clinical Global Impression and the Swanson, Nolan and Pelham Rating Scale (SNAP-IV) for ADHD. Patients who completed the study were offered the opportunity to continue into a six months open-label phase that is currently on-going. The study is a dose finding study with the primary objective of identifying effective doses in

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global

 

Related Articles (SUPN)

View Comments and Join the Discussion!

Bill Barrett Corporation Reports Fire at West Tavaputs Compressor Station in Utah

Hyatt Announces JV with Host Hotels for Hawaiian Club